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Abstract: During the last twenty years bacterial lysates have gained
a new interest and their use has obtained a progressively larger
consensus in the medical practice. They are commonly used as
immunomodulators, in order to up-regulate immune responses
against infectious damages. As a matter of fact, the role of these
lysate seems relevant in upper and lower respiratory tract infections
prevention, frequently observed both in paediatric and elder ages,
and which represent a relevant problem also in terms of socio-
economical implications. The effects of bacterial lysates as immu-
nostimulatory agents have become the central point of many studies.
The aim of those in vivo and in vitro studies was to understand and
evaluate the capacity of this kind of treatments to create a better
answer of the immune system against microbial infections, eventu-
ally leading to a reduction in their number. All the in vivo and in
vitro findings analyzed support the evidence that bacterial lysates are
powerful inducers of a specific immune response against bacterial
infections. Both in paediatric and adult clinical trials, a positive
trend has been found in terms of overall reduction of infection rates
and duration, beneficial effect on symptoms, reduction in antibi-
otics use and possibility to improve the patient’s quality of life in
several diseases. Further well-designed trials in terms of blinding
and randomization procedures and including a higher number of
patients, selected according to the disease and its severity, are
needed.
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INTRODUCTION
Bacterial lysates have recently gained a new interest andtheir use has obtained a progressively larger consensus in
the medical practice. Both researchers and medical doctors
are lately focusing on the use of bacterial lysates for several
reasons. Recurrent infections, in particular to upper and lower
respiratory tract, are frequently observed in pediatric and
elder ages and represent a relevant problem, because they
have important socio-economical implications. At the mo-
ment, a large spectrum of different therapeutic options is
available, but it is necessary to consider that the infectious
episodes may derive from several physio-pathologic condi-
tions. The immune system in children, for instance, is often
relatively ineffective, in particular concerning the antibody
responses to infectious stimuli such virus or bacteria. On the
other hand, in elder subjects a general process of immune
senescence is commonly observed, consisting in a global
reduction of the number and the activity of the immune cells.1
To increase the immune system reactivity toward the patho-
gens, in particular the bacteria, different therapeutic strategies
can be chosen, from antibiotic prophylaxis to therapies based
on vaccinations through the use of microbial origin prepara-
tions. But what really are bacterial vaccines?
Bacterial lysates were introduced in the 1970s, when
the concept of the bacteria-derived immunomodulators ap-
peared; they are mixtures of bacterial antigens derived from
different microbic species, according to the considered ex-
tract. Antigens are obtained after a mass culture of reference
bacterial strains, using a chemical (PCBL) or mechanical
(PMBL) cellular lysis and lyophilization, then mixed in the
same proportions; excipients are added to prepare the tablets.
More often the extracts include different species (polyvalent
extracts), such as Staphylococcus Aureus, Streptococcus Viri-
dans, S. Pneumoniae, S. Pyogenes, Klebsiella Pneumoniae,
K. Ozenae, Moraxella Catarrhalis, Haemophilus Influenzae,
in amounts of billions of these bacteria.2
PMBL are produced through a process that preserves
the structure of the bacterial antigens and consists in: lysis in
vitro, fractionation of bacterial bodies and/or supernatant and
finally attainment of the particulate antigens. Because of their
immunogenic capabilities, increasing importance is given to
the significant effects that these extracts present in both
experimental and clinical contexts, such as the prevention and
the treatment of recurrent upper and lower respiratory air-
ways infections. Nevertheless, PCBL are obtained through
chemical alkaline substances and processes that may deter-
mine proteins denaturation, with a consequent lower immu-
nogenicity of the antigens themselves.
Bacterial vaccines commonly represent a prophylactic
and therapeutic strategy for sequelae to bacterial or viral
infections (ie, cold and influenza), acute and chronic bron-
chitis,3,4 anginas, pharyngitis, tonsillitis, laryngitis, rhinitis,
sinusitis, and otitis5,6; they are also indicated in case of
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infections resistant to common antibiotic treatments. Re-
cently, bacterial lysates have been supposed to be useful also
in preventing chronic obstructive pulmonary disease (COPD)
exacerbations, defined as a worsening in the patient’s, with
limited airflows, baseline dyspnoea, cough, and/or sputum
beyond day-to-day variability.7,8 Research efforts have been
recently directed to this drug class for many reasons: common
treatment strategies are frequently unsuccessful, even though
modern medicine offers several possibilities; antibiotics are
not necessary during the nonacute phase of the disease;
anti-inflammatory drugs are rarely effective and corticoste-
roids only partially modify the natural history of the disease.9
MOLECULAR AND IMMUNOLOGIC
MECHANISMS OF ACTION
Polyvalent bacterial lysates are commonly used as im-
munomodulators, to up-regulate immune responses against
infectious damages. Mucosal surfaces, including those of
gastrointestinal, respiratory, and urogenital tracts, represent
the first mechanical barrier against the invasion of bacterial,
viral and parasitic pathogens.10,11 The potentiation of both
specific and nonspecific immune responses against bacteria
can be reached with the administration of polyvalent bacteria
lysates as immunostimulators, eliciting protecting effects.
When a pathogen succeeds in overcoming the epithelial
barrier, it is recognized by the resident tissue leukocytes that,
together with the epithelial cells, recall phagocytes cells
(macrophages and neutrophils). These cells may directly
interact with bacterial membrane receptors recognizing the
pathogen-associated molecular patterns (eg, endotoxin iden-
tify Gram negative bacteria, while peptidoglycans identify
the Gram positive ones) and unequivocally correlated with
the nature of the pathogen; these receptors are called PRR
(Pattern Recognition Receptors). Otherwise, phagocytes may
recognize the pathogen indirectly, through receptors interact-
ing with proteins that opsonize the bacteria, such as antibod-
ies or proteins of the complement cascade.12 The activated
phagocyte cells show a global increase in their cytotoxic
activity, thus leading to the killing and the elimination of the
pathogen itself. In this immunologic setting, also dendritic
cells (DCs) play an important role: as a matter of fact, they
represent a link between innate and specific immune re-
sponses. DCs have the task to capture bacterial agents,
transport them to loco-regional lymph-nodes and present
specific antigens to T lymphocytes. During the presentation
phase, the DCs express costimulating molecules, such as
CD83, CD80, and CD86, and produce different cytokines that
stimulate the activation of T cells and determine their polar-
ization in TH1-cells or TH2-cells.13
To improve the immune defenses toward microbial
antigens, a strategy may be directed to DCs: potentiating their
immune activity, in fact, it is also possible to promote the
activation of both lymphocytes and phagocytes cells.
Parental vaccines do not seem to determine a mucosal
protection against pathogens, while oral, intranasal, and sub-
lingual immunization can stimulate an antigen-specific im-
munoglobulins secretion at the application site, that results in
local immune protection. Oral applications of microbial an-
tigens have been shown to induce dissemination of lymphoid
cells from the gut-associated lymphoid tissue to distant mu-
cosa-associated effector sites, such as respiratory and genito-
urinary tracts and different excretory glands, where these
elements proliferate and differentiate in effector cells.
The very first step in the immune-activation resulting
from PMBL is the recognition of the microbeparticles by a
specific group of cellular receptors, called Toll-Like Recep-
tors (TLRs), expressed on the surface of monocytic-macroph-
age membranes.14 It is a matter of fact that TLRs can directly
interact with microbial ligands and this recognition may
occur either outside [through the activation of receptors by
lipopolysaccharide (LPS), lipopeptides/lipoproteins (LP), li-
poteichoic acid (LTA) and peptidoglycan (PG)] or inside the
cell (through microbe-specific PAMPs, such as double-
stranded (ds) or single-stranded (ss) RNA and bacterial DNA
with CpG motifs. The interaction between bacterial structures
and TLRs results in the activation of resting monocytes, thus
differentiating in mature DCs, able of playing the role of
professional antigen presenting cells. This mechanism is
necessary to obtain an effective immune-stimulation through
the use of PMBL: the bacterial antigens included are able to
activate monocytic-macrophagic cells in the submucosa, in-
ducing the differentiation of immature dendritic cells in
mature ones; this step then results in a stimulation of the T
cell compartment, with significant induction and improve-
ment of the T Helper cells functioning.
PMBL may also induce B cells to differentiate in
plasmacells able to generate antibodies specifically directed
to the antigens themselves; particular attention is focused on
IgA antibodies, that allow the pathogen opsonization and the
after phagocytosis and killing mediated by professional im-
mune competent cells. Secretory IgA (sIgA) have a strategic
position on mucosal surfaces and represent one of the first
protective factors of the specific immune system against
invading pathogens. Several studies have demonstrated that
the administration of bacterial lysates induces the production
of mucosal antigen-specific IgA at the application site and in
the secretions, resulting in a local protection against bacterial
infections.
Ismigen, a PMBL preparation of 8 different bacterial
strains tested in vitro has shown to induce the activation of
DCs, leading to a significantly higher expression of costimu-
lating membrane molecules (CD80, CD83, CD86).15 Further-
more, another study16 demonstrated that this PMBL had
several immunologic effects consisting in:
1. Activation of the IL-2 receptor (IL-2R-) on different
lymphocyte subsets (B, CD4 T, and CD8 T cells)
involved both in humoral and cellular immune responses
(IL-2, in an autocrine manner, is essential for the clonal
expansion of proliferating cells);
2. Induction of cytokine synthesis (IL-2, IL-10, IL-12,
IFN-) in immune competent cells, promoting regulating
immune responses;
3. Generation of CD4 and CD8 effector T cells.
The same study group analyzed the effect, in vivo, of the
PMBL (orally administrated) in preventing recurrent infec-
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tions of the upper respiratory tract (URTIs) in a group of
patients with a medical history of URTI recurrence.17 Clinical
results were correlated to the levels of IgM memory B cells
and the expression of the activation marker CD25 in periph-
eral blood lymphocytes using the flow cytometric method,
before and at 1 and 3 months after the treatment. PMBL have
shown to exert a therapeutic and preventing effect in acute
and recurrent infections of the upper airways, which is sig-
nificantly correlated with the activation and enhancement of
both IgM memory B lymphocytes (CD24/CD27 cells) and
IL-2 receptor-expressing lymphocytes (CD25 cells) in-
volved either in humoral or cellular immunity.
These results provides the capability of the investigated
PMBL to elicit both innate and specific immune responses, as
demonstrated by the significant stimulation of the expression
of cellular activation markers, at different stages. In general,
these findings suggest that the immunoprotective role of
bacterial lysates observed in human beings are related to their
immunomodulatory effect on the responses of different im-
mune competent cells, either by direct cellular activation or
through the generation and activation of immune effector
cells, and on the complex intercellular network of cytokines
production and signaling pathways.
TRIALS AND EFFICACY OF BACTERIAL LYSATES
During the last 20 years the efficacy of bacterial lysates
as immunostimulatory agents has become the central point of
many clinical trials. The aim of those studies was to under-
stand and evaluate the capacity of this kind of treatments to
create a powerful answer of the immune system against
microbial infections, eventually leading to a reduction in their
number.
These studies are quite heterogeneous. There are many
differences between the individuals enrolled concerning their
age (pediatric vs adult patients) and their suffering diseases,
including recurrent upper and lower airways infections, acute
and chronic bronchitis, rhinosinusitis, and COPD.18
We will show and discuss briefly the results of these
RCTs, to evaluate the future perspectives of using bacterial
lysates in the field of respiratory diseases but it is important
to point out that the use of bacterial extracts has been recently
considered also in the treatment of other diseases besides
respiratory illnesses, such as rheumatoid arthritis,19 type 1
diabetes mellitus,20 allergic rhinitis, asthma,21,22 chronic si-
nusitis,23 acute recurrent diverticulitis,24 chronic colitis,25,26
and inflammatory bowel disease,27 chronic and recurrent
urinary tract infections,28 periodontitis.29 Furthermore, differ-
ent studies investigate the effect of bacterial lysates on human
lymphocytes and macrophages functions in vitro and in vivo,
for a better understanding of the mechanisms that support
their clinical efficacy and an improvement of their use in both
infectious and noninfectious pathologies.
PEDIATRIC TRIALS: RESULTS
Concerning pediatric trials, the first example and one of
the most cited, is a study of 1980 written by Oehling et al30
that showed a reduction of symptoms severity using bacterial
lysates but there is no control group: this study cannot be
considered a correct example of RCT. Different clinical trials
show negative results: for example in 1986 a study involving
825 children in the treatment group and 327 in the placebo
one demonstrated that the administration of a bacterial lysate
applied intranasally for 6 months did not reduce the number
of acute respiratory diseases compared with placebo.31
Other studies, instead, revealed the benefits of bacterial
lysates use. In a RCT where children with rhinosinusitis
underwent a treatment with bacterial lysate (OM-85BV), a
decrease in infectious episodes incidence and duration , their
number and the duration of concomitant treatments; further-
more, the clinical response showed a correlation with an
increase in serum levels of IgA (active 6.53  0.96 vs
placebo 6.81  0.8).32
A trial involving 423 children attending day-care cen-
ters in which there were subjects with a higher risk of
infection, showed that during the period of treatment with
bacterial lysate, treated children had a relative lower risk to
present 3 or more episodes of upper respiratory infections.33
In another study, 56 young patients affected by sub-
acute sinusitis were involved in a RCT with the duration of 6
months, to evaluate the possible positive effects of bacterial
lysates (OM- 85BV) added to amoxicillin/clavulanate. The
results showed that the symptoms improved in the group that
underwent the combination therapy, and these patients had a
lower incidence of respiratory infections (active 1.56  0. 3
vs placebo 2.22  0. 43).34
Another RCT involving 188 pediatric patients put in
evidence that the rate of infection was reduced by 50% in
treated patients, and this protection was sustained for half a
year after the end of drug administration; drug reactions were
few, transient, expected and non serious.35
In another trial, 54 children aged 1–12 years were
followed and divided in 2 groups (active/placebo). During the
study number and duration of acute respiratory tract infec-
tions, and the number of antibiotic courses needed, were
registered. The results showed a reduction in the number of
infectious episodes, and a more significant reduction in both
antibiotic requirements and duration of the infection episodes
in the treated group compared with placebo (5.04  1.99 vs
8.0  2.55).36 A RCT including 232 children aged 3–5 years
showed that the treatment with PMBL significantly reduced
the rate of upper respiratory tract infections (16% decrease in
pharyngitis and otitis media) , being this reduction higher in
children affected more frequently by this kind of infections;
the drug was also safe and well tolerated compared with
placebo (P  0.05).37
A pilot study involving 89 children pointed out that the
administration of PMBL could lead to a significant decrease
in recurrent respiratory infections, compared with the control
group represented by the same children during the previous
year (7.84 vs 4.78, P  0.05 with PMBL; 6.78 vs 4.78, P 
0.05 without PMBL); also phlogosis indexes were signifi-
cantly lower in the treated group, and the values of B-
lymphocytes were found to be increased (9.9 with PMBL vs
5.9 without PMBL).38
In another study involving patients from 3 to 6 years of
age affected by recurrent respiratory infections and IgG
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deficiency a RCT proved the beneficial effect of bacterial
lysate.39 Others studies with young patients are in progress in
these years; after this pediatric examples we try to analyze the
results of bacterial lysate in trials with adult patients.
ADULT TRIALS: RESULTS
The first studies of bacterial lysates in the field of
respiratory diseases go back to the 1980s, when the bacterial
extracts began to be considered and studied with more atten-
tion in the clinical practice. In 1989, Heintz et al designed a
double-blind placebo controlled trial to test the efficacy of
bacterial lysates in treating patients suffering from chronic
purulent sinusitis. This study, carried over on 284 patients for
a duration of 6 months, showed the efficacy of treatment in
reducing purulent nasal discharge, cough, and headache, on
the basis of the score of symptoms.40
A RCT performed in 1994 focused its attention on
acute bronchitis and pneumonia, in 354 patients living in
institutions for elderly; the aim of the trial was to assess the
effects of using bacterial lysates in relation to lower respira-
tory tract infections incidence. The authors observed a reduc-
tion of 28% of infections, and this was because of a 40%
reduction in episodes of acute bronchitis, with no differences
in the incidence of pneumonia in the 2 groups. During the 6
months of duration of the trial, a larger number of patients in
the active treatment group presented no episodes of acute
bronchitis and a reduction of antibiotics needed in the same
group observed.41
Another RCT involving 104 patients affected by
chronic bronchitis, comparing bacterial lysates (OM-85BV)
to placebo over a period of 6 month showed a significant
reduction of the duration and symptoms of acute episodes in
the treatment group, with a concomitant sparing-effect on the
use of antibiotics, an increase in serum IgA levels and in
T-lymphocyte counts.42
In a recent Italian study, 140 patients with a medical
history of recurrent URTIs were randomly assigned to 3
groups: the first group received, by sublingual administration,
a PMBL (Ismigen) obtained by mechanical lysis of 48 billion
bacteria commonly responsible for upper respiratory tract
infections; the second one received an oral immunoregulating
lysate obtained by chemical lysis of 36 billion bacteria
(CLBL); the third one, as control group, did not receive any
immunostimulating treatment. The number of URTIs, was
significantly lower in the PMBL group with respect to the
other groups (P  0.05). Furthermore, patients treated with
PMBL group remained free from respiratory infections epi-
sodes, compared with the other groups. The duration of these
episodes and the number of working days lost were signifi-
cantly lower in the PMBL group during treatment and fol-
low-up periods. None of the patients treated with PMBL
needed concomitant assumption of antibiotics, while 9 pa-
tients of the CLBL group received such treatment (P 0.05).
Furthermore, no adverse events were described. The study
showed the efficacy of the 2 treatments, but the best results
were achieved with the use of PMBL in comparison to those
achieved with placebo and CLBL.43
Similarly, another Italian study carried out in 47 nuns
(aged 25–80 years) suffering from recurrent infections of the
upper respiratory tract has found that during the treatment and
the follow-up phases the number of respiratory infections and
their duration were statistically significantly lower in the
group treated with a PMBL, than in the placebo group.
Furthermore, in the PMBL group a significant increase of
serum immunoglobulins (IgG 35%; IgM 86%; IgA
80%) and salivary IgA (110%) was observed, in compar-
ison to baseline, while no significant differences were found
in the placebo group. All these beneficial effects of bacterial
lysates during the treatment period lengthened also during a
3 months follow-up and no adverse events related to the
medication trial were described in both groups.44 The clinical
efficacy of bacterial lysates is confirmed also by another
survey involving patients suffering from both respiratory
infections and otitis media. As a matter of fact, the bacterial
lysate treatment was associated with a significant reduction in
the frequency and duration of infectious episodes, incidence
of fever, ancillary therapies and number of working days-lost;
furthermore, changes in both immunologic (such as increased
serum concentrations of immunoglobulins) and auditory
function parameters were observed.45
The efficacy of microbial extracts has been studied and
demonstrated in chronic pulmonary illnesses, such as COPD.
The most common and serious complications of COPD are
represented by periodic exacerbations in which the role of
bacterial infections is really important: H. influenzae is the
causal agent in more than half of all bacterial exacerbations,
S. pneumoniae and M. catarrhalis for a further third, but also
Mycoplasmas and viruses are also involved. The rightful
place of antibiotic therapy is debated and there are also many
controversies and different opinions about the use of antimi-
crobial drugs, their real clinical efficacy and the possible
adverse events. As a matter of fact, only 18–25% of patients
receiving home therapy do not respond to initial treatment:
these findings suggest that the respiratory pharmacokinetics
could be suboptimal, or bacteria are becoming progressively
drug-resistant or, finally, the antibiotic therapy is not com-
pletely effective or powerful.46–48
Stimulating the immune responses against pathogens
could represent a powerful strategy to improve the quality of
life of COPD patients. One of the first RCT on the use of
bacterial lysates in COPD patients, lasting 6 months and
involving 265 patients, demonstrated a statistically significant
reduction of infectious events, and a concomitant reduction in
the use of antibiotics.49 Another RCT recruited 381 patients
with COPD followed for a 6 months period. The risk of
having one or more exacerbations during the 6 months period
was similar in both groups, but the most significant results
showed a clear reduction in the total number of days of
hospitalization for respiratory problems in the group treated
with bacterial lysate compared with the placebo group; in
addiction, the overall risk of being hospitalized was reduced
for the same patients group (16.2% vs 23.2%). Furthermore,
the number of deaths observed was reduced in the treatment
group (2 vs 6), but without statistical significance.50 These
results showed that immunostimulating agents could be use-
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ful for treating patients with COPD, being able to reduce the
likelihood of severe respiratory events possibly responsible
for hospitalization.
Another study involving 90 patients considered differ-
ent endpoints: the frequency of acute exacerbations, lung
function, parameters symptom scores, all analyzed during 1
year after the end of the treatment. The results showed that, in
the group treated with bacterial lysate (OM-85BV) compared
with the placebo group a decrease in incidence, duration, and
severity of acute exacerbation occurred, and an improvement
in symptom scored, a reduction in the course of antibiotics
and a higher bacterial clearance rate in sputum cultures.51
A systematic review and metanalysis was published in
200452; the central point of the study was the use of oral
purified bacterial extracts in the treatment of patients affected
by COPD. An extensive and systematic search for random-
ized clinical trials in all the electronic databases, biographies,
and data from manufacturers was performed; a total of 13
studies, corresponding to almost 2000 patients, were included
in the analysis. Concerning the prevention of exacerbations,
the data were globally heterogeneous and the difference
between active bacterial lysates and placebo did not reach
statistical significance, but the metanalysis also showed a
shorter duration of exacerbations in the active treated group
and the improvement of respiratory symptoms, as assessed
both by patients and physicians. Although this large system-
atic review did not find bacteria lysates to be beneficial in the
prevention of COPD exacerbations, it did find trends toward
shorter duration of exacerbation and reduction in hospitaliza-
tion, with consequent important economic consequences. It is
also important the benefit on symptoms as a reflection of a
better quality of patients life.
In a double-blind multicenterd study, 178 patients were
randomized into 2 different groups, one treated with PMBL
and the other with placebo during a 3 months period, 10 day
per month. At the end of the treatment, patients were clini-
cally followed for 9 months. Selected clinical endpoints were
seen to be significantly lower in the group treated with the
lysate than in the placebo group: the exacerbations frequency
(215 vs 248 cases) and duration (10.6 vs 15.8 days) , antibi-
otic consumption (270 doses) and hospitalization time (275
vs 590 days).53 In another study, it was investigated the
PMBL addition to therapy for COPD patients consisting in
salmeterol/fluticasone, 63 patients were randomly divided in
2 groups (A and B); all patients were treated with salmeterol/
fluticasone 50/500 mg bid.
Thirty-three subjects also received one capsule of
PBML daily the first 10 days of 3 consecutive months (group
B). This treatment was repeated 3 months after the end of the
first course. During the study, respiratory symptoms (such as
amount and color of sputum, severity of dyspnoea, frequency
of cough, fever), concomitant medications (antibiotics and
oral corticosteroids), and hospitalization were registered. At
the end of 12 months of follow-up it was clear that PBML had
reduced the total number of exacerbations (23 of 30 patients
in group A and 21 of 33 patients in group B), the number of
exacerbations per patient per year (0.67 in group A and 0.54
in group B); the number of exacerbations that needed treat-
ment with oral corticosteroids (52% in group A and 43% in
group B) and the rate of hospitalization (4/30 [0.13] in group
A and 3/33 [0.09] in group B). There were no significant
differences between the 2 groups regarding the exacerbation
symptoms, but a decreased need of antibiotics was observed
in group B.54
DISCUSSION AND CONCLUSION
Both in pediatric and adult trials, a positive trend in the
results can be found: a reduction in infection rates and
duration and use of antibiotics, plus a beneficial effect on
symptoms. We have to bear in mind there are also new
clinical perspectives and approaches about the potential use
of bacterial lysates in different pathologies, besides the com-
mon respiratory illnesses, with possibility to improve the
patient’s quality of life in several different diseases. In con-
clusion, although these findings are encouraging, more RCT
are needed to further elucidate the mechanism of action of
bacterial lysates.
According with Braido et al18 we need further trials
including a higher number of selected patients and well-
designed trials in term of blinding and randomization proce-
dures. These studies will help us to find stronger evidence of
bacterial lysates beneficial effects on symptoms improve-
ment, infections prevention and, most of all, on quality life of
our patients. A further analysis of mechanism of actions of
bacterial lysates on animals and humans are ongoing and
needed.
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